Home hemodialysis

Tablo® Hemodialysis System Receives FDA Clearance for Home Dialysis

Retrieved on: 
Thursday, April 2, 2020

Currently, more than 500,000 Americans undergo dialysis treatments three or more times each week, typically lasting four hours per treatment.

Key Points: 
  • Currently, more than 500,000 Americans undergo dialysis treatments three or more times each week, typically lasting four hours per treatment.
  • A prospective, multicenter, home hemodialysis trial with 30 patients was completed in 2019 and confirmed the Tablo system is safe and effective for home use.
  • Over the years, he has had thousands of dialysis treatments at various centers as well as on home hemodialysis.
  • Requiring only an electrical outlet and tap water to operate, the mobile Tablo system frees patients and providers from expensive clinic infrastructure.

Spectral Provides Update on the Commercial Development of its SAMI Device for Continuous Renal Replacement Therapy

Retrieved on: 
Thursday, April 2, 2020

The commercialization of SAMI, an innovative and easy-to-use CRRT (continuous renal replacement therapy) device, is progressing as planned.

Key Points: 
  • The commercialization of SAMI, an innovative and easy-to-use CRRT (continuous renal replacement therapy) device, is progressing as planned.
  • Dialco remains actively engaged in the path toward 510k clearance by the Food and Drug Administration (FDA) for its DIMI home hemodialysis device.
  • We believe that the onboarding of these two new customers validates the value proposition of our SAMI device in the CRRT marketplace.
  • Spectral, through its wholly owned subsidiary, Dialco Medical Inc. (Dialco), is also commercializing a new proprietary platform, SAMI, targeting the renal replacement therapy (RRT) market.

Dialysis Industry Leaders Come Together to Fight Public Health Crisis

Retrieved on: 
Tuesday, March 31, 2020

This collaboration will support dialysis patients with COVID-19 in their continued treatment by creating a safety network of dialysis clinics that focus on patients affected by the novel coronavirus.

Key Points: 
  • This collaboration will support dialysis patients with COVID-19 in their continued treatment by creating a safety network of dialysis clinics that focus on patients affected by the novel coronavirus.
  • These safety clinics will be equipped and managed with infection control designed for patients suspected of being impacted by COVID-19.
  • The company provides patients with their choice of a full range of quality incenter and athome dialysis modalities.
  • U.S. Renal Care serves over 26,000 patients in 338 dialysis facilities across 32 states and the Territory of Guam.

Fresenius Medical Care North America Advances Home Dialysis with New Telehealth Solution

Retrieved on: 
Wednesday, February 26, 2020

WALTHAM, Mass., Feb. 26, 2020 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA), the nation's leading provider of kidney care products and services, today announced the planned rollout of a new telehealth solution for its home dialysis patients.

Key Points: 
  • WALTHAM, Mass., Feb. 26, 2020 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA), the nation's leading provider of kidney care products and services, today announced the planned rollout of a new telehealth solution for its home dialysis patients.
  • Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions.
  • Through its industry-leading network of dialysis facilities, outpatient cardiac and vascular labs and urgent care centers, Fresenius Medical Care North America provides coordinated healthcare services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Telehealth App Helps Connect Dialysis Patients Treating at Home

Retrieved on: 
Wednesday, February 26, 2020

DENVER, Feb. 26, 2020 /PRNewswire/ -- DaVita Kidney Care achieved another industry first by incorporating a secure telehealth platform, DaVita Care Connect, into its home dialysis program.

Key Points: 
  • DENVER, Feb. 26, 2020 /PRNewswire/ -- DaVita Kidney Care achieved another industry first by incorporating a secure telehealth platform, DaVita Care Connect, into its home dialysis program.
  • "Home dialysis is a better clinical option for many patients, but it is a big responsibility," said Dr.Martin Schreiber, chief medical officer for Home Dialysis at DaVita Kidney Care.
  • "Care Connect gives our patients a convenient way to access connected care to help grow confidence in treating at home."
  • DaVita Care Connect is one component of DaVita's Home Dialysis Connect technology suite, which has impacted nearly 18,000 patients since 2018.

Quanta to Present at the 40th Annual Dialysis Conference

Retrieved on: 
Friday, January 24, 2020

Alcester, Warwickshire, UK, 24 January 2020: Quanta Dialysis Technologies Ltd (Quanta or the Company), a British med-tech company that has developed SC+, a personal haemodialysis (HD) system, today announces that the Company will be presenting at the 40th Annual Dialysis Conference (ADC), which runs from 8 to 11 February 2020, at the Kansas City Convention Center, Missouri, USA.

Key Points: 
  • Alcester, Warwickshire, UK, 24 January 2020: Quanta Dialysis Technologies Ltd (Quanta or the Company), a British med-tech company that has developed SC+, a personal haemodialysis (HD) system, today announces that the Company will be presenting at the 40th Annual Dialysis Conference (ADC), which runs from 8 to 11 February 2020, at the Kansas City Convention Center, Missouri, USA.
  • In addition, Quanta announces it has filed a 510(k) submission with the FDA for SC+, with a follow-up study planned to then extend use to Home HD.
  • SC+ has been designed to make home dialysis accessible to more patients, supporting the objectives of the Advancing American Kidney Health Initiative.
  • Full details of the session are as follows:
    Quanta will also be presenting a poster at ADC, reporting on the annual therapy cost of dialysis when using SC+ in Canada.

Quanta to Present at the 40th Annual Dialysis Conference

Retrieved on: 
Friday, January 24, 2020

Alcester, Warwickshire, UK, 24 January 2020: Quanta Dialysis Technologies Ltd (Quanta or the Company), a British med-tech company that has developed SC+, a personal haemodialysis (HD) system, today announces that the Company will be presenting at the 40th Annual Dialysis Conference (ADC), which runs from 8 to 11 February 2020, at the Kansas City Convention Center, Missouri, USA.

Key Points: 
  • Alcester, Warwickshire, UK, 24 January 2020: Quanta Dialysis Technologies Ltd (Quanta or the Company), a British med-tech company that has developed SC+, a personal haemodialysis (HD) system, today announces that the Company will be presenting at the 40th Annual Dialysis Conference (ADC), which runs from 8 to 11 February 2020, at the Kansas City Convention Center, Missouri, USA.
  • In addition, Quanta announces it has filed a 510(k) submission with the FDA for SC+, with a follow-up study planned to then extend use to Home HD.
  • SC+ has been designed to make home dialysis accessible to more patients, supporting the objectives of the Advancing American Kidney Health Initiative.
  • Full details of the session are as follows:
    Quanta will also be presenting a poster at ADC, reporting on the annual therapy cost of dialysis when using SC+ in Canada.

Two-Year Ellipsys Data Featured at Annual Controversies in Dialysis Access (CiDA) Meeting

Retrieved on: 
Wednesday, December 18, 2019

SAN JUAN CAPISTRANO, Calif., Dec. 18, 2019 /PRNewswire/ -- A landmark two-year follow-up study on the Ellipsys Vascular Access System was highlighted at the annual Controversies in Dialysis Access (CiDA) meeting, one of the premier dialysis access medical conferences in the world.

Key Points: 
  • SAN JUAN CAPISTRANO, Calif., Dec. 18, 2019 /PRNewswire/ -- A landmark two-year follow-up study on the Ellipsys Vascular Access System was highlighted at the annual Controversies in Dialysis Access (CiDA) meeting, one of the premier dialysis access medical conferences in the world.
  • The Ellipsys System from Avenu Medicalis a non-surgical alternative to creating vascular access for end-stage renal disease (ESRD) patients who require hemodialysis.
  • The meeting is the leading educational forum for surgeons, radiologists, nephrologists and medical staff who care for dialysis access patients.
  • The company's Ellipsys Vascular Access System is an innovative, ultrasound-guided, single catheter endoAVF system used to percutaneously create an arteriovenous (AV) fistula for hemodialysis access.

Dialyze Direct Expands to Five Additional Skilled Nursing Facilities in Indiana

Retrieved on: 
Wednesday, December 11, 2019

BROOKLYN, N.Y., Dec.11, 2019 /PRNewswire/ -- Dialyze Direct, a leading kidney care innovation company, today announced the expansion of their next-generation home dialysis services to five additional skilled nursing facilities (SNF) across the state of Indiana.

Key Points: 
  • BROOKLYN, N.Y., Dec.11, 2019 /PRNewswire/ -- Dialyze Direct, a leading kidney care innovation company, today announced the expansion of their next-generation home dialysis services to five additional skilled nursing facilities (SNF) across the state of Indiana.
  • Dialyze Direct has experienced tremendous demand in the Midwest for its proprietary outcome-driven dialysis model due to the recent implementation of the new Patient Driven Payment Model (PDPM).
  • This adds to the more than 100 facilities across the country in which Dialyze Direct is already operational.
  • Dialyze Direct has operations in Florida, Illinois, Indiana, Maryland, New Jersey, New York, Ohio, Pennsylvania and Texas, and is in the process of launching operations in an additional four states.

Robert Ehrlich Joins Dialyze Direct's Strategic Advisory Board

Retrieved on: 
Wednesday, October 30, 2019

BROOKLYN, N.Y., Oct. 30, 2019 /PRNewswire/ --Dialyze Direct, a leading kidney care innovation company specializing in advancements in home dialysis service and technology, today announced that former Fresenius Chairman Robert Ehrlich has joined their Strategic Advisory Board.

Key Points: 
  • BROOKLYN, N.Y., Oct. 30, 2019 /PRNewswire/ --Dialyze Direct, a leading kidney care innovation company specializing in advancements in home dialysis service and technology, today announced that former Fresenius Chairman Robert Ehrlich has joined their Strategic Advisory Board.
  • Ehrlich is well known across industries for leading high-growth companies as they journey towards acquisition or public offering.
  • Having served for a decade as Chairman and CEO of Fresenius, the world's largest dialysis company, Ehrlich brings a rich knowledge of the dialysis industry and its history to Dialyze Direct.
  • During his tenure with the dialysis giant, Ehrlich grew its revenue from $16 million to $3 billion over the course of 10 years.